Category: cell press

Cancer Cell issues big correction over “incorrectly cropped” figures, other issues

cancer cell A 2014 Cancer Cell paper became the subject of an erratum in January 2015, shortly after PubPeer members began criticizing the data. However, many issues brought up by commenters weren’t addressed in the correction notice, including a figure that might be two experiments spliced together to look like one.

The paper, led by Guido Franzoso at Imperial College London, claims that a new cancer drug called DTP3 kills myeloma cells “without causing any toxic side effects,” according to a press release from the school. Guido Franzoso is the founder of Kesios Therapeutics, a drug company which is set to begin clinical trials on DTP3.

The correction indicates that Western blots were cropped badly, which omitted several panels discussed in the text, while an “extra time point” was included accidentally. An antibody was also omitted from the description of the procedure.

PubPeer commenters have noticed additional issues, such as a criticism of figure 3D, which were not included or changed in this correction.

Here’s the correction for “Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors”: Continue reading Cancer Cell issues big correction over “incorrectly cropped” figures, other issues

Cabbage batch skids: new experiments dry up plant paper

current biologyProminent plant researcher Mark Estelle has retracted a paper on plant hormones after follow-up studies showed the conclusions were incorrect.

The hormone in question, auxin, is a major player in plant growth and development. The retracted Current Biology paper reported that a certain auxin receptor, designated AFB4, downregulates the responses of cabbage-cousin Arabidopsis thaliana to the signaling molecule. But after publication, the researchers experimented with a mutant seedling that didn’t produce the receptor, and discovered it didn’t overreact to auxin signals, indicating the receptor wasn’t playing a major role in limiting the effects.

Estelle, a Howard Hughes Medical Institute investigator based at the University of California, San Diego, told us he and his team are working on a paper that will contain the accurate data from the paper, along with new findings.

Here’s the notice for “The AFB4 Auxin Receptor Is a Negative Regulator of Auxin Signaling in Seedlings”, which has 62 citations, per Google Scholar: Continue reading Cabbage batch skids: new experiments dry up plant paper

Researchers retract paper for which first author won an award — but won’t sign notice

Bernasconi_Premio_Roche2012_small
Riccardo Bernasconi

Most of the authors of two Molecular Cell papers have retracted them after becoming aware of inappropriate image manipulation by the first author of both — who refused to sign the notices.

One of the papers, “Role of the SEL1L:LC3-I Complex as an ERAD Tuning Receptor in the Mammalian ER,” earned first author Riccardo Bernasconi, who successfully defended his PhD in 2010, the STSBC-Roche Diagnostics award in 2012. Here’s the notice for that paper: Continue reading Researchers retract paper for which first author won an award — but won’t sign notice

“I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

douglas_melton
Doug Melton

Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.

Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.

The interest was driven by the hormone’s potential as a new treatment for diabetes. In 2013, Melton told the Harvard Gazette that betatrophin could be in clinical trials within three to five years. Here’s Kerry Grens in The Scientist: Continue reading “I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

Structure error sinks NIH-MIT-SNU peptide paper

CHBIOL_21_9.c1.inddA mistake in structure identification has sunk a paper by researchers at the NIH, MIT, and Seoul National University in the Cell Press journal Chemistry and Biology.

Here’s the notice for “Peptide-Based Inhibitors of Plk1 Polo-box Domain Containing Mono-anionic Phosphothreonine Esters and Their Pivaloyloxymethyl Prodrugs”: Continue reading Structure error sinks NIH-MIT-SNU peptide paper

Cell retraction of Alzheimer’s study is second for Tufts neuroscientist

Domnez_Gizem
Gizem Donmez, via Tufts

A researcher at Tufts University has retracted a paper in Cell, a year after retracting a study on a similar subject from the Journal of Biological Chemistry.

Here’s the notice for “SIRT1 Suppresses β-Amyloid Production by Activating the α-Secretase Gene ADAM10,” a 2010 paper by Tufts’ Gizem Donmez, MIT’s Leonard Guarante — of longevity research fame — and colleagues: Continue reading Cell retraction of Alzheimer’s study is second for Tufts neuroscientist

Immunology paper retracted for inappropriate presentation but “no evidence of intentional misconduct”

immun40_4.c1.inddA paper in Immnunity has been retracted after two separate panels determined some of the figures “inappropriately presented” the data but cleared the team of wrongdoing.

However, the original data are now unavailable, according to the notice, so there’s no way to know if the paper’s conclusions are sound.

Here’s the notice for “Suppressors of Cytokine Signaling 2 and 3 Diametrically Control Macrophage Polarization”: Continue reading Immunology paper retracted for inappropriate presentation but “no evidence of intentional misconduct”

Geneticist retracting four papers for “significant problems”

jbc 620Benjamin Barré, a genetics researcher who recently set up his own group at the University of Angers, is retracting four papers he worked on as a graduate student and postdoc.

Neil Perkins, in whose lab Barré was a postdoc, and Olivier Coqueret, in whose lab he did his PhD, tell Retraction Watch: Continue reading Geneticist retracting four papers for “significant problems”

Authors retract Current Biology study following criticism on PubPeer and university investigation

current biologyThe authors of a Current Biology paper published online in February of this year have retracted it after voluminous criticism on post-publication review site PubPeer and a university committee found evidence of figure manipulation.

The paper, “Agonist-Induced GPCR Shedding from the Ciliary Surface Is Dependent on ESCRT-III and VPS4,” was co-authored by Hua Jin and Livana Soetedjo, a graduate student in Jin’s lab. Soetedjo was first author, and Jin was corresponding author.

The comments at PubPeer began on March 24: Continue reading Authors retract Current Biology study following criticism on PubPeer and university investigation

Update: Lab head shares “painful” process that led to Molecular Cell retraction

molecular cell 14Last month, we published a guest post by Jean Hazel Mendoza about the retraction of a Molecular Cell paper for sampling errors, flawed analysis, and and miscalculation.

Mendoza heard back from Jean-François Allemand, the head of one of the labs involved. Allemand tells Retraction Watch by email that when his group tried to repeat the experiment, they suspected of “missing” or “averaging” of data points in the retracted paper: Continue reading Update: Lab head shares “painful” process that led to Molecular Cell retraction